These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6800691)

  • 41. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum lipids and high-density-lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel.
    Nilsson CG; Kostiainen E; Ehnholm C
    Int J Fertil; 1981; 26(2):135-7. PubMed ID: 6114067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women.
    Toddywalla VS; Mehta S; Virkar KD; Saxena BN
    Contraception; 1980 Mar; 21(3):217-23. PubMed ID: 7389350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparative study of norplant-2 and levonorgestrel-releasing intrauterine devices].
    Wang SL
    Zhonghua Fu Chan Ke Za Zhi; 1990 Jul; 25(4):232-4, 253. PubMed ID: 2119982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian function during use of a levonorgestrel-releasing IUD.
    Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
    Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T.
    Andersson K; Batar I; Rybo G
    Contraception; 1992 Dec; 46(6):575-84. PubMed ID: 1493717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study.
    Nilsson CG; Luukkainen T; Diaz J; Allonen H
    Lancet; 1981 Mar; 1(8220 Pt 1):577-80. PubMed ID: 6110819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Influence of Norplant contraceptive implants on lactation and infant growth].
    Díaz S; Herreros C; Juez G; Peralta O; Croxatto HB
    Rev Chil Obstet Ginecol; 1985; 50(5):421-8. PubMed ID: 3939621
    [No Abstract]   [Full Text] [Related]  

  • 53. Levonorgestrel concentrations in maternal and infant serum during use of subdermal levonorgestrel contraceptive implants, Norplant, by nursing mothers.
    Shaaban MM; Odlind V; Salem HT; Abdullah KA; Gomaa AA
    Contraception; 1986 Apr; 33(4):357-63. PubMed ID: 3089681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette.
    Back DJ; Bates M; Breckenridge AM; Hall JM; MacIver M; Orme ML; Park BK; Rowe PH
    Contraception; 1981 Mar; 23(3):229-39. PubMed ID: 6786829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation.
    Faundes A; Alvarez F; Brache V; Tejada AS
    Int J Gynaecol Obstet; 1988 Jun; 26(3):429-33. PubMed ID: 2900174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endometrial morphological changes in IUD users: a review.
    Sheppard BL
    Contraception; 1987 Jul; 36(1):1-10. PubMed ID: 3117492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki PL; Luukkainen T
    Fertil Steril; 1984 Jan; 41(1):52-5. PubMed ID: 6420203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia.
    Andersson JK; Rybo G
    Br J Obstet Gynaecol; 1990 Aug; 97(8):690-4. PubMed ID: 2119218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Levels of contraceptive seroids in breast milk and plasma of lactating women.
    Saxena BN; Shrimanker K; Grudzinskas JG
    Contraception; 1977 Dec; 16(6):605-13. PubMed ID: 606500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of various IUDs on the composition of cervical mucus.
    Jonsson B; Landgren BM; Eneroth P
    Contraception; 1991 May; 43(5):447-58. PubMed ID: 1914458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.